Urology News and Research

Latest Urology News and Research

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

6 Nov 2009

Incontinence has a significant impact on caregiver's life

Incontinence in a parent, grandparent or spouse has a significant emotional impact on a caregiver's life, according to a survey released today by Caring.com and SCA, the makers of TENA® (www.tena.us).

6 Nov 2009

Changes in PSA over time aid prostate cancer detection

The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection.

6 Nov 2009

Combination therapy before prostate removal may prevent recurrence of cancer

Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.

4 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

Watson Pharmaceuticals announces third quarter 2009 financial results

Watson Pharmaceuticals, Inc. today reported net income of $63.0 million, or $0.55 per diluted share for the third quarter ended September 30, 2009. Excluding special items as detailed in the reconciliation table below, adjusted net income for the third quarter was $76.1 million, or $0.66 per diluted share, an increase of $22.1 million or 41 percent over the adjusted net income for the third quarter ended September 30, 2008. As detailed in the attached reconciliation table, adjusted EBITDA for the third quarter was $178.4 million.

4 Nov 2009

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008.

4 Nov 2009

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2009. For the quarter CPEX reported revenues of $5.0 million and a net loss of $872,000.

4 Nov 2009

Comparative study reveals similar brain networks in human and monkey brains

A study published this week in PNAS provides a comprehensive comparative functional anatomy study in human and monkey brains which reveals highly similar brain networks preserved across evolution.

4 Nov 2009

Predictive Biosciences commences clinical trials of its bladder cancer assay

Predictive Biosciences Inc. today announced the publication of pilot study results in the November issue of the Journal of Urology, highlighting the Company’s novel urinary biomarker approach to bladder cancer detection that achieves exceptionally high Negative and Positive Predictive Values (NPV and PPV).

4 Nov 2009

AAPM Task Group issues new radiation guidelines for brachytherapy

Radiation dose delivered to the prostate and nearby organs in every brachytherapy procedure should be carefully analyzed using post-implant CT or MRI and uniformly documented in every patient, according to a new guideline co-authored by Yan Yu, Ph.D., director of Medical Physics in the department of Radiation Oncology at Thomas Jefferson University.

3 Nov 2009

Patients who acquire SSTIs in healthcare settings may stay longer in hospitals to control the infection

Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.

31 Oct 2009

Public concern can undermine flu vaccination campaigns

The effectiveness of pandemic flu vaccination campaigns - like that now underway for H1N1 - could be undermined by the public incorrectly associating coincidental and unrelated health events with the vaccines.

31 Oct 2009

Hyperthermia therapy delivered through BSD Medical's system improves survival rate for bladder cancer patients

BSD Medical Corporation today announced that published study results demonstrated improvement in overall survival, tumor response rates, and local tumor control from the addition of hyperthermia therapy, delivered using the BSD-2000 Hyperthermia System, to the standard treatment regimen for 45 patients with high-risk bladder cancer.

30 Oct 2009

P&G's global branded prescription pharmaceutical business acquired by Warner Chilcott

Warner Chilcott plc announced today it has completed the acquisition of The Procter & Gamble Company's global branded prescription pharmaceutical business. The acquisition complements Warner Chilcott's existing presence in women's health care and adds new therapeutic and geographic markets.

30 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

29 Oct 2009

Allergan reports operating results for the third quarter of 2009

Allergan, Inc. today announced operating results for the quarter ended September 30, 2009. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2009 to stockholders of record on November 9, 2009.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Endo Pharmaceuticals

Endo Pharmaceuticals today reported financial results for the third quarter of 2009.

29 Oct 2009

Neogenomics declares third quarter 2009 financial results; significantly improved liquidity position

NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2009.

29 Oct 2009

Urology News and Research

Latest Urology News and Research

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Incontinence has a significant impact on caregiver's life

Changes in PSA over time aid prostate cancer detection

Combination therapy before prostate removal may prevent recurrence of cancer

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

Watson Pharmaceuticals announces third quarter 2009 financial results

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

Comparative study reveals similar brain networks in human and monkey brains

Predictive Biosciences commences clinical trials of its bladder cancer assay

AAPM Task Group issues new radiation guidelines for brachytherapy

Patients who acquire SSTIs in healthcare settings may stay longer in hospitals to control the infection

Public concern can undermine flu vaccination campaigns

Hyperthermia therapy delivered through BSD Medical's system improves survival rate for bladder cancer patients

P&G's global branded prescription pharmaceutical business acquired by Warner Chilcott

Eisai reports global Phase III study results of eribulin mesylate

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Allergan reports operating results for the third quarter of 2009

Third-quarter fiscal 2009 results announced by Endo Pharmaceuticals

Neogenomics declares third quarter 2009 financial results; significantly improved liquidity position

Innovation in neuroscience drug discovery - eBook eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Urology News and Research

Latest Urology News and Research

Innovation in neuroscience drug discovery - eBook eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in